Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 5Phase 1 2Phase 1/2 1

Status

Completed 31Recruiting 29Active not recruiting 13Terminated 12Unknown 9Withdrawn 5Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5

Conditions

Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 102Prostatic Neoplasms 66Multiple Myeloma 64Neoplasm Metastasis 63Colorectal Neoplasms 63Neoplasms 59Lung Neoplasms 52Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 40Lymphoma 40Leukemia, Lymphocytic, Chronic, B-Cell 36Pancreatic Neoplasms 34Melanoma 34Head and Neck Neoplasms 27Glioblastoma 26Rectal Neoplasms 25Ovarian Neoplasms 25Lymphoma, Large B-Cell, Diffuse 25Leukemia 24Brain Neoplasms 24Squamous Cell Carcinoma of Head and Neck 23Hematologic Neoplasms 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Myelodysplastic Syndromes 20Colonic Neoplasms 20Triple Negative Breast Neoplasms 19Lymphoma, Non-Hodgkin 19

Interventions

durvalumab 1cemiplimab 1balstilimab 1MEDI0457 1Gabapentin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Oropharyngeal Neoplasms × Clear all
NCT05363709 2026-05-12

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms

NCT03423264 2024-07-31

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

University of Chicago

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms

NCT05535023 2023-09-13

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT04001413 2022-07-29

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms

NCT04044950 2020-09-22

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡